Medium Dose of Cytarabine and Mitoxantrone

• Conditions: Chemotherapy; Acute Myelogenous Leukemia
• Interventions: Device: Flow Cytometer; Drug: Mitoxantrone; Drug: Cytarabine

• Registration Number: NCT04024241
• Lead Sponsor: Shenzhen People's Hospital

Brief Summary

By observation of the inpatients in shenzhen people's hospital,research the curative effect of the two chemotherapy schemes on AML-High dose of cytarabine and HAM.

Detailed Description

The patients of AML in shenzhen people's hospital were randomly divided into two therapy groups.One group was treated by High dose of cytarabine ,and the other was HAM.Evaluate the two chemotherapy schemes by bone marrow suppression time and patient survival time.

Study Timeline

• Study Start: 2017-09-01
• Status Verified: 2019-07
• Study First Submitted: 2019-07-16
• Study First Submitted QC: 2019-07-16
• Last Update Submitted: 2019-07-16
• Study First Posted: 2019-07-18
• Last Update Posted: 2019-07-18
• Primary Completion: 2019-08-31
• Study Completion: 2019-08-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

people diagnosed as AML

Exclusion Criteria

• acute promyeloytic leukemia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
high dose of cytarabine	Flow Cytometer	high dose of cytarabine
HAM	Flow Cytometer	medium dose of cytarabine and mitoxantrone
HAM	Mitoxantrone	medium dose of cytarabine and mitoxantrone
high dose of cytarabine	Mitoxantrone	high dose of cytarabine
HAM	Cytarabine	medium dose of cytarabine and mitoxantrone
high dose of cytarabine	Cytarabine	high dose of cytarabine

Primary Outcome Measures

Name	Time	Method
patient survival time	three years	disease free survival
bone marrow suppression time	one month	time of agranulocytosis

Trial Locations

Locations (1)

Shenzhen; 🇨🇳 Shenzhen, Guangdong, China